Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer

  • Authors:
    • M. Pistelli
    • Z. Ballatore
    • A. Santinelli
    • T. Biscotti
    • F. Piva
    • G. Occhipinti
    • A. Della Mora
    • A. Pagliacci
    • N. Battelli
    • L. Bastianelli
    • M. De Lisa
    • R. Bracci
    • E. Maccaroni
    • R. Berardi
    • S. Cascinu
  • View Affiliations

  • Published online on: June 22, 2016     https://doi.org/10.3892/or.2016.4903
  • Pages: 755-762
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The significance of phosphorylated mTOR (p-mTOR) expression is unknown in triple-negative breast carcinoma (TNBC). The aims of the present study were to assess the expression of p-mTOR in early TNBC and to evaluate possible correlations between androgen receptor (AR) expression, clinicopathological parameters and disease outcome. Between January 2009 and December 2013, all consecutive patients who were diagnosed and completed the treatment of invasive TNBC at our institution were eligible for this analysis. Patients with stage IV disease were excluded. The evaluation of p-mTOR immunohistochemical staining was semi-quantitatively considering both the percentage of positive tumor cells (range, 0-100%) and staining intensity (range, 0-3+). Ninety-eight TNBC patients were included. Approximately 33% of cases were p-mTOR positive and there was no association between positive immunostaining for p-mTOR and DFS (p=0.74) and OS (p=0.81). p-mTOR positivity was associated with small tumor size (p=0.03) and AR expression (p=0.04). High expression of p-mTOR may drive tumor proliferation in almost one third of TNBC. The biological association between mTOR activation and AR pathway suggests that there may exist a subgroup of TNBC in which the combination of both AR antagonism and mTOR inhibition should have a synergistic effect on cell growth and tumor progression.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 36 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pistelli M, Ballatore Z, Santinelli A, Biscotti T, Piva F, Occhipinti G, Della Mora A , Pagliacci A, Battelli N, Bastianelli L, Bastianelli L, et al: Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. Oncol Rep 36: 755-762, 2016.
APA
Pistelli, M., Ballatore, Z., Santinelli, A., Biscotti, T., Piva, F., Occhipinti, G. ... Cascinu, S. (2016). Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. Oncology Reports, 36, 755-762. https://doi.org/10.3892/or.2016.4903
MLA
Pistelli, M., Ballatore, Z., Santinelli, A., Biscotti, T., Piva, F., Occhipinti, G., Della Mora, A. ., Pagliacci, A., Battelli, N., Bastianelli, L., De Lisa, M., Bracci, R., Maccaroni, E., Berardi, R., Cascinu, S."Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer". Oncology Reports 36.2 (2016): 755-762.
Chicago
Pistelli, M., Ballatore, Z., Santinelli, A., Biscotti, T., Piva, F., Occhipinti, G., Della Mora, A. ., Pagliacci, A., Battelli, N., Bastianelli, L., De Lisa, M., Bracci, R., Maccaroni, E., Berardi, R., Cascinu, S."Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer". Oncology Reports 36, no. 2 (2016): 755-762. https://doi.org/10.3892/or.2016.4903